Jeremie Calais, M.D., MSc
Positions & Affiliations:
Director, Clinical Research Program, Ahmanson Translational Theranostics Division, DMMP; Associate Professor, Ahmanson Translational Theranostics Division, DMMP; Faculty Member, Jonsson Comprehensive Cancer Center; Faculty Member, Institute of Urologic Oncology; Faculty Member, Physics and Biology in Medicine Graduate Program
Honorary Board Member, SNMMI Correlative Imaging Council (CIC), Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Committee Member, Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, University of Melbourne
Fueled by the adoption of Positron Emission Tomography (PET/CT) and stimulated by major new Theranostics and therapeutic opportunities in prostate cancer and neuroendocrine tumors, the Ahmanson Translational Division and Nuclear Medicine clinic has expanded significantly. Novel therapeutic approaches, together with advanced molecular imaging assays, have given rise to the field of Theranostics, the combination of tumor-specific targeted radionuclide imaging and therapy. Very specific clinical and research expertise is now required to master all aspects of Nuclear Medicine, Molecular Imaging and Theranostics. Dr. Jeremie Calais MD MSc has established a clinical Theranostics research program that combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and therapy. The clinical research program focuses on translatable radiolabeled theranostic pairs that can be used and applied for diagnosis and therapy of cancer. The clinical research program involves close collaboration with clinical faculty across many departments at UCLA (Urology, Radiation Oncology, Radiology, Medical Oncology, Oncologic Surgery) but also with multiple national and international collaborators. The Theranostics Clinical Research Program is conducting clinical trials to determine the impact of PSMA PET imaging and PSMA radionuclide therapy on care and outcome of patients with prostate cancer. The division has submitted jointly with UCSF an academic NDA for 68Ga-PSMA-11, a major achievement for academia. Recently the research program is also conducting exploratory clinical studies of FAPI PET targeting the tumor stroma (fibroblast activation protein) in multiple cancers. FAP is a new promising target for nuclear Theranostics.
Associate Professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He leads the clinical research program of Nuclear Medicine and Theranostics at UCLA that combines radionuclide therapy and imaging.